Aptorum Group Ltd Class A
$ 0.84
0.36%
10 Feb - close price
- Market Cap 6,833,400 USD
- Current Price $ 0.84
- High / Low $ 0.88 / 0.82
- Stock P/E N/A
- Book Value 3.15
- EPS -0.32
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.14 %
- 52 Week High 4.47
- 52 Week Low 0.69
About
Aptorum Group Ltd Class A is a London-based biotechnology company focused on the development and commercialization of innovative therapeutic solutions for critical health challenges, particularly in infectious diseases and oncology. The firm possesses a diverse pipeline of proprietary drug candidates, underpinned by advanced research and technological capabilities. By prioritizing unmet medical needs, Aptorum Group aims to accelerate the market introduction of its novel therapies, thereby significantly contributing to the pharmaceutical landscape and enhancing health outcomes globally.
Analyst Target Price
$80.00
Quarterly Earnings
| Sep 2025 | Mar 2025 | Sep 2024 | Mar 2023 | Jun 2022 | Mar 2022 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-18 | 2025-04-30 | 2024-12-20 | 2023-04-28 | 2022-09-30 | 2022-04-29 | 2021-09-15 | 2021-04-19 | 2021-03-31 | 2020-12-31 | 2020-09-01 | 2020-04-29 |
| Reported EPS | -0.06 | -0.29 | -0.5 | -2.22 | -0.05 | -0.25 | -0.47 | 0.38 | -0.2346 | 0.1889 | -0.21 | -0.33 |
| Estimated EPS | None | 0 | 0 | None | -3 | -3.3 | -3 | -3.1 | 0 | 0 | 0 | 0 |
| Surprise | 0 | -0.29 | -0.5 | 0 | 2.95 | 3.05 | 2.53 | 3.48 | -0.2346 | 0.1889 | -0.21 | -0.33 |
| Surprise Percentage | None% | None% | None% | None% | 98.3333% | 92.4242% | 84.3333% | 112.2581% | None% | None% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APM
2026-02-02 12:57:49
Aptorum Group announced a collaboration between its subsidiary DiamiR Biosciences and Instant NanoBiosensors (INB) to validate INB's automated APOE testing platform for Alzheimer’s disease risk assessment. This validation will occur in DiamiR's CLIA-certified and CAP-accredited laboratory, comparing INB's G8 Genotyping Analyzer to DiamiR's New York State approved APOE test. The goal is to evaluate the platform's performance, clinical suitability, and potential to enhance testing throughput for Alzheimer's disease diagnosis.
2025-11-02 11:40:18
DiamiR Biosciences and Aptorum Group announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This approval allows DiamiR to offer its validated APOE Genotyping molecular testing in various biological samples through its CLIA-certified and CAP-accredited clinical laboratory to licensed healthcare providers in New York State and nationwide. The milestone enhances diagnostics capabilities for the merging companies.
2025-10-26 05:02:20
Aptorum Group (APM) has regained compliance with Nasdaq's minimum bid price requirement by maintaining a closing bid price of at least $1.00 for ten consecutive business days between July 16 and July 30, 2025. This resolution addresses an earlier notice from Nasdaq dated April 15, 2025. Additionally, Aptorum announced a definitive all-stock merger agreement with DiamiR Biosciences, a company specializing in blood-based brain health tests, which will become a wholly-owned subsidiary of Aptorum.
2025-10-26 05:02:20
Aptorum Group Limited announced its intention to acquire URF Holding Group Limited, a company focused on urban revitalization in China, through a non-binding Letter of Intent and Term Sheet. The acquisition, which involves a reverse takeover, will result in Aptorum distributing its existing businesses to pre-acquisition shareholders. U Group's strategy targets China's "Generation Z" consumption growth through curated shopping experiences and community rejuvenation, with significant revenues reported for 2020 and 2021.
2025-10-26 05:02:20
Aptorum Group Limited announced the completion of a private offering of a $3 million convertible note due in December 2023. The note was solely subscribed by Aenco Technologies Limited, an entity indirectly owned by Aptorum's Non-Executive Director and major shareholder, Mr. Ian Huen. Proceeds will fund research and development of therapeutic candidates, its liquid biopsy diagnostics program, commercialization of NativusWell®, and general corporate purposes.
2025-10-26 05:02:20
YOOV Group Holding Limited has cancelled its acquisition of Aptorum Group Limited in a reverse merger transaction that was initially announced on March 1, 2024. The deal, valued at $250 million, would have resulted in YOOV shareholders owning approximately 90% of the combined company. As part of the termination agreement, YOOV is required to reimburse Aptorum for 90% of incurred expenses, up to $1,000,000.
